Suppr超能文献

亚洲初治转移性肾细胞癌患者总生存的新预后分类。

A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma.

机构信息

Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

出版信息

Cancer Sci. 2012 Sep;103(9):1695-700. doi: 10.1111/j.1349-7006.2012.02351.x. Epub 2012 Jul 11.

Abstract

The aims of the present study were to: (i) develop a clinically useful prognostic classification in Asian patients with metastatic renal cell carcinoma (RCC) by combining metastatic features with several pretreatment parameters; and (ii) evaluate the validity of this prognostic classification. Baseline characteristics and outcomes were collected for 361 patients who underwent interferon-α-based therapy between 1995 and 2005. Relationships between overall survival (OS) and potential prognostic factors were assessed using Cox's proportional hazard model. The predictive performance of the model was evaluated using bootstrap resampling procedures and by using an independent dataset obtained from randomly selected institutions. The predictive accuracy was measured using the concordance index (c-index). Four factors were identified as independent prognostic factors: time from initial diagnosis to treatment, anemia, elevated lactate dehydrogenase (LDH), and poor prognostic metastatic group (liver only, bone only, or multiple organ metastases). Each patient was assigned to one of three risk groups: favorable risk (none or one factor; n = 120), in which median OS was 51 months; intermediate risk (two factors; n = 101), in which median OS was 21 months; and poor risk (three or four factors; n = 102), in which median OS was 10 months. The c-index was 0.72 in the original dataset and 0.72 in 500 random bootstrap samples. In the independent dataset for external validation, the c-index was 0.73. Thus, the new prognostic classification is easily applicable for Asian patients with previously untreated metastatic RCC and should be incorporated into patient care, as well as clinical trials performed in Asia.

摘要

本研究的目的是

(i)通过将转移特征与几种预处理参数相结合,为亚洲转移性肾细胞癌(RCC)患者建立一种临床有用的预后分类;(ii)评估该预后分类的有效性。收集了 1995 年至 2005 年间接受干扰素-α 为基础治疗的 361 例患者的基线特征和结果。使用 Cox 比例风险模型评估总生存(OS)与潜在预后因素之间的关系。通过自举重采样程序和从随机选择的机构获得的独立数据集来评估模型的预测性能。使用一致性指数(c-index)来衡量预测准确性。确定了四个独立的预后因素:从初始诊断到治疗的时间、贫血、乳酸脱氢酶(LDH)升高和不良预后的转移组(仅肝转移、仅骨转移或多个器官转移)。每位患者被分配到三个风险组之一:低危组(无或一个因素;n = 120),中位 OS 为 51 个月;中危组(两个因素;n = 101),中位 OS 为 21 个月;高危组(三个或四个因素;n = 102),中位 OS 为 10 个月。原始数据集中的 c-index 为 0.72,500 个随机自举样本中的 c-index 为 0.72。在外部验证的独立数据集,c-index 为 0.73。因此,新的预后分类易于适用于未经治疗的亚洲转移性 RCC 患者,应纳入患者护理以及在亚洲进行的临床试验。

相似文献

1
A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma.
Cancer Sci. 2012 Sep;103(9):1695-700. doi: 10.1111/j.1349-7006.2012.02351.x. Epub 2012 Jul 11.
6
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530.
9
Neutrophil number after interferon-alfa treatment is an independent predictive marker of overall survival in metastatic renal cell carcinoma.
Clin Genitourin Cancer. 2012 Sep;10(3):180-4. doi: 10.1016/j.clgc.2012.03.006. Epub 2012 May 18.
10
Metastatic renal carcinoma comprehensive prognostic system.
Br J Cancer. 2003 Feb 10;88(3):348-53. doi: 10.1038/sj.bjc.6600768.

引用本文的文献

4
Serum lactate dehydrogenase levels predict the prognosis of patients with soft tissue sarcoma.
Mol Clin Oncol. 2022 Mar;16(3):65. doi: 10.3892/mco.2022.2498. Epub 2022 Jan 19.
5
Clinical Characteristics and Prognosis of Renal Cell Carcinoma With Spinal Bone Metastases.
Front Oncol. 2021 Jun 16;11:659779. doi: 10.3389/fonc.2021.659779. eCollection 2021.
6
Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.
Int J Clin Oncol. 2021 Oct;26(10):1947-1954. doi: 10.1007/s10147-021-01979-9. Epub 2021 Jun 30.
9
Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
Cancer Sci. 2020 Jul;111(7):2460-2471. doi: 10.1111/cas.14449. Epub 2020 Jun 12.

本文引用的文献

3
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.
J Natl Compr Canc Netw. 2011 Feb;9 Suppl 1(0 1):S1-29. doi: 10.6004/jnccn.2011.0124.
4
6
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.
9
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验